- Home
- NAPA vs MNKD Comparison
NAPA vs MNKD Comparison
Compare NAPA & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAPA
- MNKD
- Stock Information
- Founded
- NAPA 1976
- MNKD 1991
- Country
- NAPA United States
- MNKD United States
- Employees
- NAPA N/A
- MNKD N/A
- Industry
- NAPA Beverages (Production/Distribution)
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- NAPA Consumer Staples
- MNKD Health Care
- Exchange
- NAPA Nasdaq
- MNKD Nasdaq
- Market Cap
- NAPA 1.6B
- MNKD 1.8B
- IPO Year
- NAPA 2021
- MNKD 2004
- Fundamental
- Price
- NAPA $11.08
- MNKD $6.27
- Analyst Decision
- NAPA Hold
- MNKD Strong Buy
- Analyst Count
- NAPA 8
- MNKD 5
- Target Price
- NAPA $10.51
- MNKD $8.40
- AVG Volume (30 Days)
- NAPA 1.5M
- MNKD 2.8M
- Earning Date
- NAPA 12-05-2024
- MNKD 11-07-2024
- Dividend Yield
- NAPA N/A
- MNKD N/A
- EPS Growth
- NAPA N/A
- MNKD N/A
- EPS
- NAPA 0.39
- MNKD 0.08
- Revenue
- NAPA $425,914,000.00
- MNKD $267,200,000.00
- Revenue This Year
- NAPA $22.74
- MNKD $45.36
- Revenue Next Year
- NAPA $6.79
- MNKD $16.99
- P/E Ratio
- NAPA $28.19
- MNKD $74.80
- Revenue Growth
- NAPA 7.19
- MNKD 51.35
- 52 Week Low
- NAPA $5.38
- MNKD $3.17
- 52 Week High
- NAPA $11.10
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- NAPA 75.95
- MNKD 38.90
- Support Level
- NAPA $10.96
- MNKD $5.81
- Resistance Level
- NAPA $11.09
- MNKD $6.77
- Average True Range (ATR)
- NAPA 0.02
- MNKD 0.25
- MACD
- NAPA -0.04
- MNKD -0.07
- Stochastic Oscillator
- NAPA 83.33
- MNKD 36.44
About NAPA The Duckhorn Portfolio Inc.
The Duckhorn Portfolio Inc produces luxury and ultra-luxury wine across a portfolio of winery brands, including Duckhorn Vineyards, Paraduxx, Goldeneye, Migration, Decoy, Canvasback, Calera, Kosta Browne, Greenwing and Postmark. Its revenue is comprised of wholesale and direct-to-consumer sales. Wholesale revenue is generated through sales directly to California retailers and restaurants, sales to distributors and agents located in other states throughout the United States, and sales to export distributors that sell internationally.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.